Search

Aim: To investigate efficiency of inhacort in long-term (6 months to 2 years) treatment of bronchial asthma (BA)., Materials and Methods: 67 inpatients and 65 outpatients with moderate BA were divided into two groups. 96 patients of group 1 had received standard combined treatment without glucocorticosteroids (GCS), 36 patients of group 2 had received GCS. Inpatients were given inhacort in a dose 1000 micrograms/day, outpatients took inhacort in a daily dose 500 micrograms/day. The examination scheme included assessment of external respiration function (ERF), blood hydrocortisone, sputum rheology and diagnosis of candidosis., Results: Inhacort treatment has reduced frequency of asphyxia attacks 2.5-fold 30 and 25% of the patients stopped taking sympathomimetics and GCS, respectively. None of the patients had asphyxia as a status. ERF, sputum viscosity improved, hydrocortisone secretion was unchanged. Only 3.8% of the patients developed oral candidosis., Conclusion: Inhacort in a dose 1 mg controls BA. 73% of the patients treated outpatiently had no need in hospitalization.

Aim: The study of efficacy and safety of ingacort in severe and moderate asthma., Materials and Methods: Clinical response to ingacort, frequency of its recurrences, hospitalizations, duration of hospital stay were assessed on the treatment month 12, 24 and 36 in 58, 30 and 11 patients with bronchial asthma (BA), respectively., Results: 12 months of ingacort treatment promoted a decline in BA symptoms: day and night episodes became less frequent, requirement of beta-2-agonists decreased, bronchial obstruction regressed. Doses of systemic steroids were reduced twice or discontinued. Asthmatic statuses occurred 10 times less frequently. This effect persisted throughout the following 2 years. Side effects were registered within the first year of the treatment and emerged after local use of the drug., Conclusion: Long-term administration of ingacort in bronchial asthma is safe and effective.

Inhalation corticosteroids (beclometasone dipropionate, budesonide, flunisolide) proved effective against bronchial asthma (BA) and safe as they induce no severe systemic side effects. Of these three drugs side effects arise most frequently in administration of beclometasone dipropionate, least frequently of flunisolide. These inhalation corticosteroids are indicated both in non-steroid-dependent and steroid-dependent BA to reduce the dose of oral steroids or, if possible, for their complete discontinuation. Flunisolide is the most potent and effective of all inhalation corticosteroids used in current practice.